Glucosteril Fresenius Kabi

Glucosteril Fresenius Kabi is an intravenous solution for injection that contains glucose monohydrate as its sole active ingredient. It is supplied in a liquid form without a specified concentration, intended for parenteral administration. Marketed in the European Union, this prescription‑only product is classified as a carbohydrate solution and is used as an energy source in clinical nutrition, often incorporated into infusion protocols to maintain glucose homeostasis during surgery or care.

Glucosteril is employed in clinical settings where rapid provision of glucose is required.

- Supplementing carbohydrate calories in parenteral nutrition regimens. - Preventing hypoglycemia during peri‑operative periods. - Providing an immediate energy source for patients unable to receive enteral nutrition. - Supporting metabolic demands in critically ill or trauma patients. - Used as a diluent or carrier for compatible intravenous medications when glucose is needed.

When administered intravenously, Glucosteril may be associated with a range of observed effects.

Common: - Transient increase in blood glucose levels. - Mild hyperosmolarity at high infusion rates. - Local irritation at the infusion site. - Nausea or vomiting if administered rapidly.

Serious: - Severe hyperglycemia requiring medical intervention. - Electrolyte disturbances such as hyponatremia. - Fluid overload leading to pulmonary edema. - Allergic reactions including rash, urticaria, or anaphylaxis.

Clinicians should observe several precautions when prescribing Glucosteril to ensure patient safety.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor serum electrolytes, especially sodium and potassium, during therapy. - Use caution in patients with renal or cardiac insufficiency due to risk of fluid overload. - Avoid rapid bolus administration; prefer controlled infusion. - Verify compatibility with other IV solutions before mixing. - Consider pregnancy status; data are limited. - Document infusion parameters in the patient record.

Glucosteril can interact with other intravenous agents, influencing glucose balance or solution compatibility.

Avoid: - Co‑administration with high‑dose insulin infusions without close glucose monitoring. - Mixing with calcium‑containing solutions that may precipitate.

Use with caution: - Concurrent use of diuretics that affect electrolyte status. - Administration alongside hypertonic saline solutions. - Use with catecholamines that can increase glucose production. - Combining with other carbohydrate‑rich IV fluids may cause hyperglycemia.